LONDON, May 3, 2017 /PRNewswire/ -- Smith &
Nephew plc (LSE: SN, NYSE: SNN), a global leader in medical
technology, today announces it has signed a worldwide distribution
agreement with MolecuLight®, Inc., a developer of innovative
imaging technology for the clinical assessment of wounds.
This agreement supports Smith & Nephew's strategic priority
to innovate for value by delivering solutions that help healthcare
professionals better improve the lives of their patients.
"Smith & Nephew, through products such as
ACTICOAT™ antimicrobial silver dressings and
IODOSORB™ cadexomer gel, has long been committed to helping
customers address infection in chronic and acute wounds," said
Andy Weymann, MD, Chief Medical
Officer at Smith & Nephew. "The MolecuLight
i:X imaging device enables healthcare
professionals to see what they have never been able to see before,
the actual accumulation of several common bacteria in a wound, even
when not visible to the naked eye.
MolecuLight i:X
enhances clinicians' ability to choose the right therapy, at the
right time for their patient 1,2 In addition, it has
also the potential to enhance other areas of current wound care
practice such as helping to guide wound sampling and debridement,
monitoring of wound progression, providing more insight in
conversation between the clinician and the patient, and greater
detail when documenting treatment decisions."
Rosemary Hill, BSN, CWOCN,
CETN(C), of Lions Gate Hospital (Vancouver, Canada) added, ''The
MolecuLight i:X is more than a bacteria
visualization device. The information it is providing is positively
impacting our antimicrobial stewardship program and empowering my
overall wound treatment decision making.''
The MolecuLight i:X is a handheld
point-of-care imaging device that uses fluorescence imaging to
display potentially harmful concentrations of bacteria that
fluoresce in violet light on screen, in real-time. Clinicians
can capture and view still images and video, as well as measure the
surface area of a wound and then save and add those images to the
patient's electronic health record 2,3.
"When combined with clinical best practice, the information
provided by the MolecuLight i:X on bacterial
presence and distribution can guide early interventions to
potentially reduce bioburden and promote wound
healing2," said Craig
Kennedy, CEO MolecuLight. "Partnering with Smith &
Nephew, a world leader in advanced wound care, allows this
revolutionary technology to rapidly reach a worldwide customer base
and begin the process of becoming a routine step in wound
assessment."
The MolecuLight i:X is currently available
in Canada and the European Union
with regulatory clearance in the U.S. pending.
About MolecuLight Inc.
MolecuLight Inc. is a privately owned, Canadian medical imaging
company delivering real-time fluorescence image-guidance solutions
that provide clinicians with new information about wound bacterial
burden and wound surface area to assist clinicians in making
improved diagnostic and treatment
decisions1,2,4,5,6,7,8,9,10. The company was
founded in 2012 by Dr. Ralph
DaCosta, Principal Investigator and Scientist at the
Princess Margaret Cancer Center, University Health Network
(Toronto, Canada), currently the
company's Chief Scientific Officer and Director. MolecuLight's
premiere product - the MolecuLight i:X is
a Wound imaging Device that allows clinicians to quickly, safely
and easily visualize bacteria that fluoresce in violet light
and measure wound surface area at the point of care so they have
maximum insights for accurate treatment and accelerated healing
2.
The MolecuLight i:X™ Imaging Device is approved by
Health Canada (Medical License #95784) and has CE Marking
(Certificate # G1160292355002) for sale in the European Union. The
MolecuLight i:X™ Imaging Device is pending US FDA De Novo
approval and is not available in the US.
About Smith & Nephew
Smith & Nephew is a global medical technology business
dedicated to helping healthcare professionals improve people's
lives. With leadership positions in Orthopaedic Reconstruction,
Advanced Wound Management, Sports Medicine and Trauma &
Extremities, Smith & Nephew has around 15,000 employees and a
presence in more than 100 countries. Annual sales in 2015 were more
than $4.6 billion. Smith & Nephew
is a member of the FTSE100 (LSE: SN, NYSE: SNN).
For more information about Smith & Nephew, please visit our
website www.smith-nephew.com, follow @SmithNephewplc on Twitter or
visit SmithNephewplc on Facebook.com.
To learn more about what we do to help reduce wound infections,
please visit www.closertozero.com.
Forward-looking Statements
This document may contain forward-looking statements that may
or may not prove accurate. For example, statements regarding
expected revenue growth and trading margins, market trends and our
product pipeline are forward-looking statements. Phrases such as
"aim", "plan", "intend", "anticipate", "well-placed", "believe",
"estimate", "expect", "target", "consider" and similar expressions
are generally intended to identify forward-looking statements.
Forward-looking statements involve known and unknown risks,
uncertainties and other important factors that could cause actual
results to differ materially from what is expressed or implied by
the statements. For Smith & Nephew, these factors include:
economic and financial conditions in the markets we serve,
especially those affecting health care providers, payers and
customers; price levels for established and innovative medical
devices; developments in medical technology; regulatory approvals,
reimbursement decisions or other government actions; product
defects or recalls or other problems with quality management
systems or failure to comply with related regulations; litigation
relating to patent or other claims; legal compliance risks and
related investigative, remedial or enforcement actions; disruption
to our supply chain or operations or those of our suppliers;
competition for qualified personnel; strategic actions, including
acquisitions and dispositions, our success in performing due
diligence, valuing and integrating acquired businesses; disruption
that may result from transactions or other changes we make in our
business plans or organisation to adapt to market developments; and
numerous other matters that affect us or our markets, including
those of a political, economic, business, competitive or
reputational nature. Please refer to the documents that Smith &
Nephew has filed with the U.S. Securities and Exchange Commission
under the U.S. Securities Exchange Act of 1934, as amended,
including Smith & Nephew's most recent annual report on Form
20-F, for a discussion of certain of these factors. Any
forward-looking statement is based on information available to
Smith & Nephew as of the date of the statement. All written or
oral forward-looking statements attributable to Smith & Nephew
are qualified by this caution. Smith & Nephew does not
undertake any obligation to update or revise any forward-looking
statement to reflect any change in circumstances or in Smith &
Nephew's expectations.
Trademark of Smith & Nephew. Certain marks
registered US Patent and Trademark Office.
References:
- Wu YC, Smith M, Chu A, Lindvere-Teene L, Starr D, Tapang K,
Wong O, Linden R, DaCosta RS. Handheld fluorescence imaging device
detects subclinical wound infection in an asymptomatic patient with
chronic diabetic foot ulcer: a case report. Int Wound J. 2016
Aug;13(4):449-53.
- DaCosta RS, Kulbatski I, Lindvere-Teene L, Starr D, Blackmore
K, Silver JI, Opoku J, Wu YC, Medeiros PJ, Xu W, et al.
Point-of-care autofluorescence imaging for real-time sampling and
treatment guidance of bioburden in chronic wounds: first-in-human
results. PLoS One. 2015 Mar 19;10(3).
- Hill R and Douglas JJ. Effect of bacterial fluorescence imaging
on patient care and wound management in a hospital setting: a pilot
study. Proceedings of the Annual Symposium on Advanced Wound Care
(SAWC); 2017 Apr 5-9; San Diego, CA. (accepted poster)
- Ottolino-Perry K, Chamma E, Blackmore KM, Lindvere-Teene L,
Starr D, Tapang K, Rosen CF, Pitcher B, Panzarella T, Linden R,
DaCosta RS. Improved detection of clinically relevant wound
bacteria using autofluorescence image-guided sampling in diabetic
foot ulcers. Int Wound J. 2017; doi: 10.1111/iwj.12717.
- MolecuLight Inc. Case Study 0051 Track Wound Size and Bacterial
Presence with the MolecuLight i:X. 2016.
- Rennie MY. A prospective, single-blind evaluation of the
positive predictive value (PPV) of the MolecuLight i:X device to
predict the presence of porphyrin-producing bacteria in chronic
wounds. MolecuLight final report TR054. 2017 Jan.
- MolecuLight Inc. Case Study 0051 Track Wound Size and Bacterial
Presence with the MolecuLight i:X. 2016.
- Raizman R. Point-of-care fluorescence imaging device guides
care and patient education in obese patients with surgical site
infections. Presented at: CAWC 2016. Proceedings of the 22nd Annual
Canadian Association of Wound Care Conference; 2016 Nov 3-6, Niagara Falls,
ON.
- Raizman R. Fluorescence imaging positively predicts bacterial
presence and guides wound cleaning and patient education in a
series of pilonidal sinus patients. Proceedings of the Annual
Wounds UK Conference; 2016 Nov 14-16;
Harrogate, UK.
- Hoeflok J, Teene L, Chamma E, Chu A, DaCosta RS. Pilot clinical
evaluation of surgical site infections with a novel handheld
fluorescence imaging device. Proceedings of the Annual Military
Health System Research Symposium (MHSRS); 2014 Aug 18-21; Fort
Lauderdale, FL.
Photo:
http://mma.prnewswire.com/media/507060/Smith_and_Nephew_MolecuLight.jpg
Logo: http://mma.prnewswire.com/media/3924/smith.jpg